AR015751A1 - Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos - Google Patents
Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandosInfo
- Publication number
- AR015751A1 AR015751A1 ARP990101572A ARP990101572A AR015751A1 AR 015751 A1 AR015751 A1 AR 015751A1 AR P990101572 A ARP990101572 A AR P990101572A AR P990101572 A ARP990101572 A AR P990101572A AR 015751 A1 AR015751 A1 AR 015751A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- branched
- compounds
- alkyl
- linear
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Luminescent Compositions (AREA)
Abstract
Un compuesto de la formula (I) en la que R3, R4 y Z se seleccionan independientemente, entre hidrogeno, halo (por ejemplo, cloro, fluor, bromo o yodo),alquilo C1-4 opcionalmente sustituido con 1-3 átomos de fluor, alcoxi C1-4 opcionalmente sustituidocon 1-3 átomos de fluor, y alcoxi C1-4-alquilo C1-4, dondecada uno de los radicales alquilo puede estar opcionalmente sustituido con 1-3 átomos de fluor; W es -CH2-O-alquilo C1-6 donde el radical alquilo puede serlineal o ramificado; o W es -CH2NR1R2, donde R1 y R2 se seleccionan independientemente entre hidrogeno y alquilo C1-6 lineal o ramificado; o R1 y R2, junto conel nitrogeno al que están unidos, forman un anillo monocíclico no aromático saturado o insaturado de 4-7 miembros o un anillo bicíclico de 7-10 miembros queopcionalmente puede contener 1 o 2 heteroátomos además del nitrogeno de NR1R2, donde dichos heteroátomos se seleccionan independientemente entre oxígeno,nitrogeno y azufre, y donde de 1-3 átomos de C del anillo, o uno delos átomos del anillo, pueden ser sustituidos opcional e independientemente con alquiloC1-4 lineal o ramificado, alcoxi C1-6 lineal o ramificado, alquil C1-3 lineal o ramificado -cicloalquilo C3-7, hidroxi, amino, ciano, halo, aril-alquilo C1-3linealo ramificado o heteroarilalquilo C1-3 lineal o ramificado, donde dicho arilo se selecciona entre fenilo y naftilo y dicho heteroarilo se seleccionaentre oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, furanilo, pirazolilo, pirrolilo, tetrazolilo, triazolilo, tienilo, imidazolilo, pirazinilo, pirazolilo,indolilo, isoindolilo, pirazinilo, cinnolinilo, piridinilo y pirimidinilo; con la condicion de que en cualquier anillo formado por NR1R2: (a) no puede habermás de un átomo de oxígeno en el anillo; (b) no puede haber ningun radical hidroxi, alcoxi, alcoximetilo, ciano, amino o alquilamino unido directamente aningun átomo de nitrogeno; y (c) ningun carbono del anillo que esté unido mediante un doble enlace a otro carbono del anillo y no formaparte de un sistema deanillo aromático, puede estar unido a un átomo de oxígeno del anillo o a un átomo de nitrogeno del anillo; y las sales farmacéuticamente aceptables de tales
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8123798P | 1998-04-09 | 1998-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015751A1 true AR015751A1 (es) | 2001-05-16 |
Family
ID=22162936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101572A AR015751A1 (es) | 1998-04-09 | 1999-04-07 | Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6525048B1 (es) |
| EP (1) | EP1070065B1 (es) |
| JP (1) | JP3496759B2 (es) |
| KR (1) | KR100378931B1 (es) |
| CN (1) | CN1117092C (es) |
| AP (1) | AP1175A (es) |
| AR (1) | AR015751A1 (es) |
| AT (1) | ATE248838T1 (es) |
| AU (1) | AU749254B2 (es) |
| BG (1) | BG104915A (es) |
| BR (1) | BR9909522A (es) |
| CA (1) | CA2327782A1 (es) |
| CO (1) | CO5080727A1 (es) |
| CZ (1) | CZ20003684A3 (es) |
| DE (1) | DE69910997T2 (es) |
| DK (1) | DK1070065T3 (es) |
| DZ (1) | DZ2756A1 (es) |
| EA (1) | EA003400B1 (es) |
| ES (1) | ES2204154T3 (es) |
| HK (1) | HK1035719A1 (es) |
| HR (1) | HRP20000653A2 (es) |
| HU (1) | HUP0102400A3 (es) |
| ID (1) | ID26086A (es) |
| IL (1) | IL138629A0 (es) |
| IS (1) | IS5641A (es) |
| MA (1) | MA26619A1 (es) |
| MY (1) | MY133390A (es) |
| NO (1) | NO20005004L (es) |
| NZ (1) | NZ507010A (es) |
| OA (1) | OA11496A (es) |
| PA (1) | PA8469101A1 (es) |
| PE (1) | PE20000413A1 (es) |
| PL (1) | PL343408A1 (es) |
| PT (1) | PT1070065E (es) |
| SK (1) | SK14782000A3 (es) |
| TN (1) | TNSN99056A1 (es) |
| TR (1) | TR200002932T2 (es) |
| TW (1) | TW555758B (es) |
| WO (1) | WO1999052907A1 (es) |
| YU (1) | YU59400A (es) |
| ZA (1) | ZA992596B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) * | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| DE60026146T2 (de) * | 1999-09-03 | 2006-08-17 | Apbi Holdings, Llc | Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion |
| GB2362826A (en) * | 2000-06-02 | 2001-12-05 | Lilly Co Eli | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
| ATE409475T1 (de) * | 2001-02-20 | 2008-10-15 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
| AP2005003390A0 (en) * | 2003-03-12 | 2005-09-30 | Pfizer Prod Inc | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives. |
| CA2555172A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| AR048112A1 (es) | 2004-03-25 | 2006-03-29 | Solvay Pharm Bv | Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor |
| AR049478A1 (es) | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas. |
| MXPA06015267A (es) * | 2004-06-22 | 2007-03-15 | Pfizer Prod Inc | Antagonistas diazabiciclicos del receptor histamina-3. |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| CA2580042A1 (en) * | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106849A (en) * | 1988-05-24 | 1992-04-21 | American Home Products Corporation | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders |
| WO1990008148A1 (en) * | 1989-01-23 | 1990-07-26 | Pfizer Inc. | Bis-aza-bicyclic anxiolytic agents |
| US5157034A (en) * | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| EP0607163B1 (en) * | 1991-09-25 | 1996-12-11 | Pfizer Inc. | NEUROLEPTIC 2-SUBSTITUTED PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES |
| US5262428A (en) * | 1992-03-13 | 1993-11-16 | Wake Forest University | Biologically active tropane derivatives |
| JP2753146B2 (ja) * | 1992-06-16 | 1998-05-18 | ファイザー・インコーポレーテッド | ビス−アザー二環式抗不安薬の製法および中間体 |
| GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
| WO1996010570A1 (en) * | 1994-09-30 | 1996-04-11 | Pfizer Inc. | NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES |
| US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
-
1999
- 1999-03-17 PA PA19998469101A patent/PA8469101A1/es unknown
- 1999-03-18 TR TR2000/02932T patent/TR200002932T2/xx unknown
- 1999-03-18 AU AU32687/99A patent/AU749254B2/en not_active Ceased
- 1999-03-18 IL IL13862999A patent/IL138629A0/xx unknown
- 1999-03-18 AT AT99945686T patent/ATE248838T1/de not_active IP Right Cessation
- 1999-03-18 EA EA200000910A patent/EA003400B1/ru not_active IP Right Cessation
- 1999-03-18 US US09/403,892 patent/US6525048B1/en not_active Expired - Fee Related
- 1999-03-18 CZ CZ20003684A patent/CZ20003684A3/cs unknown
- 1999-03-18 ES ES99945686T patent/ES2204154T3/es not_active Expired - Lifetime
- 1999-03-18 BR BR9909522-0A patent/BR9909522A/pt not_active Application Discontinuation
- 1999-03-18 DE DE69910997T patent/DE69910997T2/de not_active Expired - Fee Related
- 1999-03-18 PT PT99945686T patent/PT1070065E/pt unknown
- 1999-03-18 YU YU59400A patent/YU59400A/sh unknown
- 1999-03-18 DK DK99945686T patent/DK1070065T3/da active
- 1999-03-18 CN CN99807195A patent/CN1117092C/zh not_active Expired - Fee Related
- 1999-03-18 ID IDW20002017A patent/ID26086A/id unknown
- 1999-03-18 WO PCT/IB1999/000457 patent/WO1999052907A1/en active IP Right Grant
- 1999-03-18 HU HU0102400A patent/HUP0102400A3/hu unknown
- 1999-03-18 PL PL99343408A patent/PL343408A1/xx not_active Application Discontinuation
- 1999-03-18 JP JP2000543464A patent/JP3496759B2/ja not_active Expired - Fee Related
- 1999-03-18 EP EP99945686A patent/EP1070065B1/en not_active Expired - Lifetime
- 1999-03-18 NZ NZ507010A patent/NZ507010A/en unknown
- 1999-03-18 KR KR10-2000-7011167A patent/KR100378931B1/ko not_active IP Right Cessation
- 1999-03-18 SK SK1478-2000A patent/SK14782000A3/sk unknown
- 1999-03-18 CA CA002327782A patent/CA2327782A1/en not_active Abandoned
- 1999-04-02 TW TW088105301A patent/TW555758B/zh not_active IP Right Cessation
- 1999-04-05 PE PE1999000270A patent/PE20000413A1/es not_active Application Discontinuation
- 1999-04-07 TN TNTNSN99056A patent/TNSN99056A1/fr unknown
- 1999-04-07 MY MYPI99001344A patent/MY133390A/en unknown
- 1999-04-07 DZ DZ990057A patent/DZ2756A1/xx active
- 1999-04-07 MA MA25527A patent/MA26619A1/fr unknown
- 1999-04-07 AR ARP990101572A patent/AR015751A1/es unknown
- 1999-04-08 ZA ZA9902596A patent/ZA992596B/xx unknown
- 1999-04-08 AP APAP/P/1999/001502A patent/AP1175A/en active
- 1999-04-09 CO CO99021093A patent/CO5080727A1/es unknown
-
2000
- 2000-09-26 IS IS5641A patent/IS5641A/is unknown
- 2000-10-04 HR HR20000653A patent/HRP20000653A2/hr not_active Application Discontinuation
- 2000-10-04 NO NO20005004A patent/NO20005004L/no not_active Application Discontinuation
- 2000-10-06 OA OA1200000273A patent/OA11496A/en unknown
- 2000-11-07 BG BG104915A patent/BG104915A/xx unknown
-
2001
- 2001-09-04 HK HK01106215A patent/HK1035719A1/xx not_active IP Right Cessation
-
2003
- 2003-02-11 US US10/364,804 patent/US6887905B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015751A1 (es) | Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos | |
| UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
| ES539658A0 (es) | Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados | |
| MX9203249A (es) | Derivados del acido bencimidazolin-2-oxo-1-carboxilico y composiciones farmaceuticas que los contienen. | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| DK0462884T3 (da) | TRH-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder disse | |
| ES2155535T3 (es) | Inhibidores de sintesis de apoliproteina b. | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| ES2080815T3 (es) | Derivados de la 1-naftil-piperacina, sus procedimientos de preparacion y composiciones farmaceuticas que los contienen. | |
| PE20212323A1 (es) | Formulaciones farmaceuticas | |
| CO4950607A1 (es) | Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg c o a reductasa para el tratamiento del cancer | |
| CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| ES2045083T3 (es) | Un procedimiento para preparar un compuesto quimico. | |
| AR058208A1 (es) | Derivados de indolizina,proceso de preparacion,composiciones farmaceuticas que los contienen y usos terapeuticos en alteraciones cardiovasculares. | |
| ES2069249T3 (es) | Derivados de imidazol, su procedimiento de preparacion y los compuestos farmaceuticos que los contienen. | |
| CO4980875A1 (es) | Nuevos derivados de la equinocandina, su procedimiento de preparacion y su aplicacion como fungicidas | |
| DK185984D0 (da) | Disubstituerede polymethyleniminer,fremgangsmaader til deres fremstilling og farmaceutiske kompositioner indeholdende dem | |
| MX9200665A (es) | Derivados de ureas y tioureas disubstituidas, procedimiento para su preparacion y composiciones farmaceuticas que los contiene. | |
| MX9204220A (es) | Bencimidazoles. | |
| AR125594A1 (es) | Moduladores alostéricos negativos novedosos de ciclopenta[c]pirrol de nr2b | |
| BR0002935A (pt) | Compostos tetrazolilalquil-indol como agentes antiinflamatórios e analgésicos | |
| MX9204711A (es) | Compuestos terapeuticos. | |
| TH53986A (th) | ซัลโฟนิลออกซาโซลามีนชนิดใหม่ | |
| SE8306884D0 (sv) | Akrylsyraderivat innehallande en syrehaltig heterocykel till anvendning som lekemedel, nya industriprodukter och framstellningsforfarande |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |